Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712745 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
A Early Phase 1 study of Metastasis and Cancer, Lung, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06712745 is a Early Phase 1 study of Metastasis and Cancer, Lung that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 92-participant average among 15 other Metastasis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06712745, a Early Phase 1 study of Metastasis and Cancer, Lung, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
Conditions Studied
Interventions
- RADIATION Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712745
The ClinicalTrials.gov registry entry for NCT06712745 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 15 other Metastasis trials with a reported enrollment target (67% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastasis appearing as the primary indexed condition, and to 1 intervention - of which Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR) is the first listed.
NCT06712745 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06712745 about?
NCT06712745 is a clinical study titled "Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung". The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.
What is the current status of trial NCT06712745?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-19. Estimated completion is 2028-12.
What conditions does trial NCT06712745 study?
This clinical trial studies the following conditions: Metastasis, Cancer, Lung.
What interventions are being tested in trial NCT06712745?
The interventions under investigation include: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR) (RADIATION).
Who is sponsoring clinical trial NCT06712745?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712745 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
-
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RECRUITING · Phase 1
-
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
RECRUITING · Phase 2
-
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.